Product development is a critical component of our growth, and excellent science is our key point of difference.
Our capability in the field of research and development is a key enabler to Apotex being suitably positioned to develop a robust portfolio of new products. In some cases, our R&D potential enables us to circumvent patents and litigate to bring generic products to market sooner. This pioneering competence is what sets Apotex apart.
Apotex currently has over 300 new products under development, and we are investing CAD$2 billion over the next 10 years in research and development.
At Apotex, research and development is the cornerstone of our business. Our commitment to helping enrich lives globally by providing high-quality, affordable pharmaceutical products is reflected in our ongoing state-of-the-art research and development facilities. Our Etobicoke facility in Canada is a testament to our commitment to excellence. It has been voted one of the five best new pharmaceutical plants in the world by the International Society of Pharmaceutical Engineering (ISPE), and we are proud to say that we are the largest pharmaceutical operation in Canada. With a facility footprint of more than 600,000 square feet, our Etobicoke facility makes and impact.